Navigation Links
Shire plc: Continued Strong Product Sales Performance in Q3: On Track to Deliver Significant 2011 Earnings Growth
Date:10/28/2011

rate ("CER") basis, which is a Non GAAP measure, product sales were up 25%.

Product sales in the quarter benefited from higher ADDERALL XR® sales, in part due to significantly lower sales deductions following a lowering of the estimate of inventory in the US retail pipeline.

  • The strong product sales growth more than offset declines in 3TC® and ZEFFIX® royalties, both of which are now affected by the disagreement with GlaxoSmithKline ("GSK"), to give growth in total revenues of 24%, to $1,086 million in the quarter (Q3 2010: $874 million).


 

  • As expected, research and development ("R&D") was up 21% on a Non GAAP basis compared to Q3 2010, as we continue to invest in both early and late stage programs across our business to enable us to deliver future growth. On a US GAAP basis, R&D expenditure increased 2% compared to Q3 2010.


 

  • Non GAAP operating income was up 15% to $341 million (Q3 2010: $298 million). As expected, Non GAAP operating expenses increased at broadly the same rate as the increase in product sales compared to Q3 2010. This increase was due to increased investment in our R&D program and higher selling, general and administrative ("SG&A") expenditure as we absorb the operating costs of Advanced BioHealing Inc. ("ABH") and Movetis, neither of which were incurred in Q3 2010, in addition to supporting product launches and our continued growth.


 

Non GAAP diluted earnings per American Depositary Share ("ADS") were up 10% to $1.28 (Q3 2010: $1.16), due to the higher Non GAAP operating income, partially offset by higher Non GAAP Other Expenses.

  • On a US GAAP basis, operating income was up 64% to $255 million (Q3 2010: $156 million). Q3
    '/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Related biology technology :

1. NHS Northamptonshire Chief Executive John Parkes Accepts Visiting Professorship
2. FDA Approves Shires FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE)
3. Shires Quarterly Revenues Grow by 25% to $1 Billion for the First Time
4. Shire Files Lawsuits Against Watson and Roxane for Infringement of VYVANSE(R) (lisdexamfetamine dimesylate) Patents
5. Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection)
6. Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
7. Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
8. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
9. Reportlinker Adds Shire plc: PharmaVitae Profile
10. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
11. Shire plc - Statement re ProAmatine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... VIENNA , Sept. 17, 2014 ... compelling, quantitative data from a study of the cost ... at the 50 th Annual Meeting of the ... a poster session today, Christian Frois , Ph.D., ... in a series of planned Intarcia-sponsored, retrospective studies to ...
(Date:9/17/2014)... 2014 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD) (OTCQX: ... proprietary technologies and products for advanced microarray diagnostics, today ... trading in the United States ... commence on September 17, 2014 on the OTCQX under ... on the TSX Venture Exchange under its existing symbol ...
(Date:9/17/2014)... 17 de septiembre de 2014  Cryoport, ... proveedor mundial de soluciones logísticas avanzadas criogénicas ... la vida, anunció hoy la contratación de ... con sede en Rótterdam, Países Bajos, para ... Europa en rápido crecimiento. Según los términos ...
(Date:9/17/2014)... Scotland , September 17, 2014 /PRNewswire/ ... new mode of action from a truly ... decade  MGB Biopharma, a biopharmaceutical ... anti-infectives, announces today that it has secured ... its lead antibacterial, MGB-BP-3, against a range ...
Breaking Biology Technology:Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 4Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 5SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 2SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 2Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 4Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 2MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 6MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 7
... the Nobel Prize shows a cat resting in a ... around graphene, which, at one atom thick, is the ... A significant obstacle to realizing graphene,s potential lies in ... sleeping cat. For now, material scientists stitch individual graphene ...
... Professor Federico Rosei of the INRS Energy Materials ... the prestigious 2010 Friedrich Wilhelm Bessel Research Award given ... 25 of these awards annually to young, high level ... recognition of the caliber and scope of his research ...
... ... ... ... longUrl, so we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; break; ...
Cached Biology Technology:Graphene's strength lies in its defects 2INRS professor Federico Rosei receives a 2010 Friedrich Wilhelm Bessel Research Award 2YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 2YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 3YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 4YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 5YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 6YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 7YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 8YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 9YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 10YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 11YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 12YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 13YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 14
(Date:9/17/2014)... from the Copenhagen Centre for Social Evolution and Yale ... that birth weight and -length can partially predict the ... as autism and schizophrenia later in life. The study ... subsequent hospital diagnoses for up to 30 years, and ... study is published today in the Proceedings of ...
(Date:9/17/2014)... the human retinoblastoma protein gene are a leading cause ... turned to fruit fly eyes to unlock the secrets ... paper featured on the cover of the current issue ... State University researchers provide the first detailed examination of ... the human cancer gene, said Irina Pushel, MSU undergraduate ...
(Date:9/17/2014)... 1960s. The typical development phases of trees and stands ... as much as 70 percent. This was the outcome ... Universitt Mnchen based on long-term data from experimental forest ... findings were published recently in Nature Communications . ... topic, with the very survival of large forest ecosystems ...
Breaking Biology News(10 mins):Size at birth affects risk of adolescent mental health disorders 2Size at birth affects risk of adolescent mental health disorders 3Abnormal properties of cancer protein revealed in fly eyes 2Global change: Trees continue to grow at a faster rate 2Global change: Trees continue to grow at a faster rate 3
... York University and Rockefeller University have discovered that ... have key roles in gene regulation, can team ... are a recently discovered large class of regulatory, ... in target messenger RNA to regulate their stability ...
... natural process that repairs damage to the human ... has helped establish a method of gene therapy ... disease-causing genes. , The findings are available online ... repair process known as homologous recombination, Dr. Matthew ...
... that allows immune cells known as neutrophils to protect ... at Washington University School of Medicine in St. Louis ... the development of an arthritis-like disorder by making the ... newly identified role for the gene, Foxo3a, may open ...
Cached Biology News:NYU, Rockefeller researchers find complexity of regulation by microRNA genes 2Researchers pioneer new gene therapy technique using natural repair process 2Researchers pioneer new gene therapy technique using natural repair process 3Disabling gene defuses rheumatoid arthritis in mice 2Disabling gene defuses rheumatoid arthritis in mice 3